GSK、吉利德等持续加码的HIV市场，本土创新如何迎来黄金时代？
全球HIV药物市场正以4.0%的复合年率持续增长，预计2030年将达到575亿美元。
Time：
2023-02-14 13:17
Author：
写意君
杰克说药丨一个真正的创新药的故事：吉利德衣壳抑制剂，勒那卡韦
吉利德公司的化学副总裁John Link讲述了勒那卡韦（1）的漫长而曲折的开发过程。
Time：
2023-02-08 16:30
Author：
写意君
共价还是非共价？礼来首创新药BTK激酶抑制剂Pirtobrutinib启示
Pirtobrutinib是第三代BTK抑制剂，也是第一款非共价型BTK抑制剂首创新药。
Time：
2023-02-08 10:17
Author：
杨翼
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务